StockData
MIRA Pharmaceuticals, Inc. logo

MIRA Pharmaceuticals, Inc. (MIRA) stock

MIRANasdaqPharmaceutical Preparations
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 6/30
$0.59−0.05 (-7.66%)

Close on Nov 18, 2026Market cap $24.84MP/E –Yield –

MIRA Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

MIRA Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.14M, down 21.9% year over year. For fiscal 2025 it was $1.72M, down 48.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.72M-48.0%
FY2024Dec 31, 2024$3.31M+110.1%
FY2023Dec 31, 2023$1.57M-33.1%
FY2022Dec 31, 2022$2.35M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$705.79K+42.2%
Q1 FY2026Mar 31, 2026$524.78K+66.9%
Q4 FY2025Dec 31, 2025$496.54K-42.4%
Q3 FY2025Sep 30, 2025$412.64K-61.3%
Q2 FY2025Jun 30, 2025$496.20K-19.2%
Q1 FY2025Mar 31, 2025$314.40K-58.8%
Q4 FY2024Dec 31, 2024$861.44K+122.5%
Q3 FY2024Sep 30, 2024$1.07M+5.1%
Q2 FY2024Jun 30, 2024$614.46K–
Q1 FY2024Mar 31, 2024$762.28K+180.7%
Q4 FY2023Dec 31, 2023$387.12K-56.2%
Q3 FY2023Sep 30, 2023$1.02M+42.0%
Q2 FY2023Jun 30, 2023-$101.02K–
Q1 FY2023Mar 31, 2023$271.61K–
Q4 FY2022Dec 31, 2022$884.76K–
Q3 FY2022Sep 30, 2022$714.97K–

More MIRA Pharmaceuticals figures

See a number that looks wrong?